title: The whey fermentation product malleable protein matrix decreases TAG             concentrations in patients with the metabolic syndrome: a randomised placebo-controlled             trial.
abstract: Animal and human studies suggest that a malleable protein matrix (MPM) from whey decreases plasma lipid concentrations and may positively influence other components of the metabolic syndrome such as glucose metabolism and blood pressure (BP). The primary objective of this double-blind, multi-centre trial was to investigate the effects of a low-fat yoghurt supplemented with whey MPM on fasting TAG concentrations in patients with the metabolic syndrome. A total of 197 patients were randomised to receive MPM or a matching placebo yoghurt identical in protein content (15 g/d). Patients were treated during 3 months with two daily servings of 150 g yoghurt each to compare changes from baseline in efficacy variables. MPM treatment resulted in a significantly larger reduction of TAG concentrations in comparison to placebo (relative change -16%, P=0·004). The difference was even more pronounced in subjects with elevated fasting TAG (≥200 mg/dl) at baseline (-18%, P=0·005). The relative treatment difference in fasting plasma glucose was -7·1 mg/dl (P=0·089). This effect was also more pronounced in subjects with impaired fasting glucose at baseline (-11 mg/dl, P=0·03). In patients with hypertension, the relative treatment difference in systolic BP reached -5·9 mmHg (P=0·054). The relative treatment difference in body weight was -1·7 kg (P=0·015). The most common adverse events were gastrointestinal in nature. Conclusions from the present study are that consumption of a low-fat yoghurt supplemented with whey MPM twice a day over 3 months significantly reduces fasting TAG concentrations in patients with the metabolic syndrome and improves multiple other cardiovascular risk factors.
authors: Center of Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Kerpener Street 62, 50937 Cologne, Germany. ioanna.berthold@uni-koeln.de
authors: Ioanna
authors: I
authors: Gouni-Berthold
authors: Dominik M
authors: DM
authors: Schulte
authors: Wilhelm
authors: W
authors: Krone
authors: Jean-François
authors: JF
authors: Lapointe
authors: Pierre
authors: P
authors: Lemieux
authors: Hans-Georg
authors: HG
authors: Predel
authors: Heiner K
authors: HK
authors: Berthold
mesh_terms: D000328:Adult; D000368:Aged; D002239:Carbohydrate Metabolism, Inborn Errors / Q000209:etiology / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D018752:Diet, Fat-Restricted; D004311:Double-Blind Method; D005260:Female; D005285:Fermentation; D005858:Germany / Q000453:epidemiology; D005991:Glycerol Kinase / Q000172:deficiency; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology / Q000517:prevention & control; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D000075262:Hypoadrenocorticism, Familial; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000178:diet therapy* / Q000503:physiopathology; D008875:Middle Aged; D008894:Milk Proteins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood*; D000067816:Whey Proteins; D015014:Yogurt / Q000009:adverse effects / Q000032:analysis
chemical_list: D000960:Hypolipidemic Agents; D008894:Milk Proteins; D014280:Triglycerides; D000067816:Whey Proteins; D005991:Glycerol Kinase